Schedule 13G ownership disclosure

Aquestive Therapeutics Inc

Common Stock, Par Value $0.001 Per Share · CUSIP: 03843E104

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BRATTON DOUGLAS K

    Shares: 10,077,434.00 · Class: 11.1%

  • MonoLine RX II, L.P.

    Shares: 3,468,747.00 · Class: 3.8%

  • MonoLine RX III, L.P.

    Shares: 2,657,943.00 · Class: 2.9%

  • MonoLine RX, L.P.

    Shares: 1,688,639.00 · Class: 1.9%

  • MonoLine Partners, L.P.

    Shares: 1,948,578.00 · Class: 2.1%

  • MonoSol Rx Genpar, L.P.

    Shares: 47,051.00 · Class: 0.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000897423-25-000023
Form type
SCHEDULE 13G/A
Filer
Aquestive Therapeutics, Inc.
CIK
CIK 1398733
Filed
Feb 13, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub